PubMed Health⌕ Search

Biomedical subjects

R F ESCAMILLA

Publications and source records attributed to R F ESCAMILLA.

At least 19 recordsLinked to original sources
PubMed1960

Newer hormonal preparations.

A review of the present status of various hormonal substances is presented. The pituitary preparations include various growth hormones (human and beef), still used only experimentally, thyrotropic hormone, used mainly for testing thyroid function, corticotropin-widely used-and gonadotropic hormone.Thyroid, thyroxin and triiodothyronine preparations are considered, with USP thyroid still being most useful. Glucagon may be of some use in terminating hypoglycemia - tolbutamide is now used in many older diabetic persons. New adrenal cortical steroids are still appearing and show variation in effects; cortisone or hydrocortisone remain relatively inexpensive. Many combinations are available. The newest addition to available male hormone preparations is fluoxymesterone which is anabolic in smaller dosage than the older forms. Several new long acting preparations of androgens, estrogens and progesterone are available, and many ingenious combinations are presented.

Adrenal Cortex Hormones↗
PubMed1958

Triiodothyronine; clinical effects in patients with suboptimal response to other thyroid preparations.

Thirty patients with evidence of hypometabolism or a clinically related condition were given triiodothyronine after suboptimal response to thyroxin or desiccated thyroid. DL- and L-isomers of triiodothyronine were used and compared. Thirteen patients (43.3 per cent) were improved and 17 (56.6 per cent) were unimproved or became worse. Side effects occurred in 9 of 34 trials (26 per cent), and could not always be eliminated by decreasing the dosage. The highest percentage of good response occurred in a small group (four of five) who received a combination of desiccated thyroid or thyroxin with supplemental triiodothyronine. Despite careful analysis of the data, no basis was found on which to predict which patients would receive benefit from the triiodothyronine. However, the occasional improvement, sometimes dramatic, suggested that a therapeutic trial with triiodothyronine in difficult or unresponsive cases of hypometabolism or hypothyroidism is justified.

Antineoplastic Agents, Hormonal↗